LIRENITY

Welcome to the Brand page for “LIRENITY”, which is offered here for Pharmaceutical and therapeutic preparations for the treatment of gastrointestinal, skin, multi-organ, respiratory, ophthalmic, autoimmune, cardiovascular, central nervous system, endocrine, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, psychiatric, urogenital, urological, and viral diseases and disorders; pharmaceutical and therapeutic preparations for the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic duodenitis, eosinophilic esophagitis, ulcerative colitis, crohn's disease, irritable bowel syndrome, functional gastrointestinal disease, chronic urticaria, atopic dermatitis, indolent systemic mastocytosis, mast cell activation syndrome, idiopathic pulmonary fibrosis, eosinophilic asthma, asthma, conjunctivitis, vitiligo, and viral infections;.

Its status is currently believed to be active. Its class is unavailable. “LIRENITY” is believed to be currently owned by “Allakos Inc.”